Literature DB >> 16633345

ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses.

Stamatia Papoutsopoulou1, Antony Symons, Tharsana Tharmalingham, Monica P Belich, Frank Kaiser, Dimitris Kioussis, Anne O'Garra, Victor Tybulewicz, Steven C Ley.   

Abstract

The TPL-2 MEK kinase is essential for activation of the Erk MAP kinase pathway during innate immune responses. TPL-2 is found in complex with ABIN-2 (A20-binding inhibitor of NF-kappaB 2). Here, using antigen-presenting cells from ABIN-2-deficient mice, we show that ABIN-2 was required for optimal activation of Erk induced by receptors that signal via TPL-2, including Toll-like receptor 4 and tumor necrosis factor receptor 1 in macrophages, and CD40 in B cells. ABIN-2 was necessary for the maintenance of TPL-2 protein stability. In contrast, ABIN-2 deficiency did not affect agonist-induced regulation of transcription factor NF-kappaB. Stimulation of ABIN-2-deficient macrophages via Toll-like receptor 4 showed that different thresholds of Erk signaling were required for optimal induction of tumor necrosis factor and interleukin 1beta. Thus, ABIN-2 acts to positively regulate the Erk signaling potential by stabilizing TPL-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633345     DOI: 10.1038/ni1334

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  45 in total

Review 1.  A20: central gatekeeper in inflammation and immunity.

Authors:  Beatrice Coornaert; Isabelle Carpentier; Rudi Beyaert
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

Review 2.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

3.  Coordinate regulation of TPL-2 and NF-κB signaling in macrophages by NF-κB1 p105.

Authors:  Huei-Ting Yang; Stamatia Papoutsopoulou; Monica Belich; Christine Brender; Julia Janzen; Thorsten Gantke; Matt Handley; Steven C Ley
Journal:  Mol Cell Biol       Date:  2012-06-25       Impact factor: 4.272

4.  p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation.

Authors:  Ana Risco; Carlos del Fresno; Agnes Mambol; Dayanira Alsina-Beauchamp; Kirsty F MacKenzie; Huei-Ting Yang; Domingo F Barber; Carmen Morcelle; J Simon C Arthur; Steven C Ley; Carlos Ardavin; Ana Cuenda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

5.  Emergence of the A20/ABIN-mediated inhibition of NF-κB signaling via modifying the ubiquitinated proteins in a basal chordate.

Authors:  Shaochun Yuan; Xiangru Dong; Xin Tao; Liqun Xu; Jie Ruan; Jian Peng; Anlong Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

Review 6.  Regulation of NF-κB by deubiquitinases.

Authors:  Edward W Harhaj; Vishva M Dixit
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

7.  ABIN2 Function Is Required To Suppress DSS-Induced Colitis by a Tpl2-Independent Mechanism.

Authors:  Sambit K Nanda; Tsunehisa Nagamori; Mark Windheim; Sylvia Amu; Gabriella Aviello; Janet Patterson-Kane; J Simon C Arthur; Steven C Ley; Padraic Fallon; Philip Cohen
Journal:  J Immunol       Date:  2018-10-24       Impact factor: 5.422

Review 8.  Ubiquitin in NF-kappaB signaling.

Authors:  Yu-Hsin Chiu; Meng Zhao; Zhijian J Chen
Journal:  Chem Rev       Date:  2009-04       Impact factor: 60.622

9.  Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production.

Authors:  Lisa A Mielke; Karen L Elkins; Lai Wei; Robyn Starr; Philip N Tsichlis; John J O'Shea; Wendy T Watford
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions.

Authors:  Brian K Weaver; Erwin Bohn; Barbi A Judd; M Pilar Gil; Robert D Schreiber
Journal:  Mol Cell Biol       Date:  2007-05-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.